Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in CRSP.

← Back to Free Index

CRSP

Analysis as of: 2026-06-28

CRISPR Therapeutics AG

CRISPR Therapeutics develops gene-edited, cell therapy, and gene-silencing medicines, led by shared economics in CASGEVY and a broader wholly owned pipeline.

biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

First product proven, platform rerating still pending

The company has already crossed the hardest credibility threshold with an approved CRISPR therapy. The investment case now turns on whether that proof expands into repeatable commercial economics and at least one more clearly underwritable franchise.

Analysis

Thesis

CRISPR Therapeutics already has first-product proof, a strong balance sheet, and multiple 2026-2027 shots on goal; if CASGEVY becomes a steadier commercial annuity and just one owned platform clears clinical proof, the stock can rerate from cash-plus-optionality to a credible multi-franchise editing company by 2031.

Last Economy Alignment

AI should improve design, target selection, and development speed, but value still depends on regulated trust, clinical proof, and manufacturing. This is helped by AI, not transformed by it.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.9x (from 5 most recent analyses)

Reasoning

The upside does not require every program to work. A steadier CASGEVY ramp, one validated owned in vivo franchise, and one additional credible engine in autoimmune, oncology, or siRNA would likely be enough for investors to value the business as a real platform company rather than mostly cash plus distant options.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The biggest risk is proof conversion, not near-term liquidity. If CASGEVY remains operationally bottlenecked and the 2026-2027 owned-program updates fail to show repeatable efficacy and manufacturability, the stock can remain trapped near cash plus a discounted partner-led asset instead of rerating into a broad platform story.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No material company-specific clinical or commercial disclosure appeared in the last 7-10 days, so the core setup is unchanged.
The next repricing surfaces are still mid-2026 CTX460 timing and H2 2026 data windows for CTX310, CTX611, and zugo-cel.
June governance filings expanded equity compensation capacity, but did not change cash runway or the platform thesis.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.46

They own real gene-editing know-how, regulatory credibility, and some manufacturing, so AI can help them design and learn faster. But the money still depends on slow things AI cannot wish away: approvals, safety, treatment-center execution, and how much value Vertex captures on the lead product.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$83.74

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research